The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical/pathologic features and survival of patients with fibrolamellar-hepatocellular carcinoma (FLL-HCC): Data from the Fibrolamellar-Hepatocellular (FLL-HCC) Consortium.
C. Ang
No relevant relationships to disclose
A. P. Venook
No relevant relationships to disclose
M. A. Choti
No relevant relationships to disclose
R. P. DeMatteo
No relevant relationships to disclose
R. K. Kelley
No relevant relationships to disclose
D. Cosgrove
No relevant relationships to disclose
J. P. McGuire
No relevant relationships to disclose
M. S. Torbenson
No relevant relationships to disclose
T. M. Pawlik
No relevant relationships to disclose
W. R. Jarnagin
No relevant relationships to disclose
M. I. D'Angelica
No relevant relationships to disclose
Y. Fong
No relevant relationships to disclose
J. F. Chou
No relevant relationships to disclose
E. M. O'Reilly
No relevant relationships to disclose
D. S. Klimstra
No relevant relationships to disclose
A. C. Griffin
No relevant relationships to disclose
G. P. Vallarapu
No relevant relationships to disclose
M. Capanu
No relevant relationships to disclose
D. P. Kelsen
No relevant relationships to disclose
G. K. Abou-Alfa
No relevant relationships to disclose